title: [Treatment of pemphigus with intravenous immunoglobulin].
abstract: BACKGROUND
  The interest of intravenous immunoglobulins (Igi.v.) in the treatment of pemphigus is discussed. Pemphigus is not a recognized indication for this treatment by the CEDIT (French Committee for the assessment and diffusion of technological innovations). The aim of this study was to assess the efficacy of Igi.v. in the treatment of severe corticosteroid-dependent or resistant pemphigus.
  
  
  METHODS
  A retrospective study using a standardized questionnaire was conducted in the various departments of dermatology among the "Groupe Bulles" of the French Society of Dermatology. The study collected the following information from 12 patients suffering from pemphigus and treated with Igi.v.: 1) general demographical data; 2) characteristics of the pemphigus; 3) different treatments applied, and 4) efficacy and side effects of treatments.
  
  
  RESULTS
  Among the 12 patients studied at the end of treatment with Igi.v., 8 were in complete remission (1 fleetingly for 2 months and 1 preceding initiation of Igi.v.), and 2 were improved (1 temporarily for 4 months). A reduction in corticosteroid therapy was possible in 75 p. 100 of cases (9 patients). During treatment with Igi.v., immunosuppressors were combined with oral corticosteroids in 3 cases. It was possible to reduce their dose 1 one case and to stop them in another case. No major side effect related to treatment with Igi.v. was observed. Six months and one year after the treatment, complete remission rates were respectively 6/10 and 5/8. One patient relapsed more than one year after the end of Igi.v. treatment.
  
  
  CONCLUSIONS
  Although very expensive, treatment with Igi.v. appears of interest in the treatment of severe corticosteroid-dependent or resistant pemphigus. Moreover tolerance is excellent. The results of our study warrant confirmation in a prospective study.
authors.affiliation: Service de Dermatologie, Hôpital Bichat Claude Bernard, AP-HP, Paris.
authors.forename: A
authors.initials: A
authors.lastname: Levy
authors.forename: M-S
authors.initials: MS
authors.lastname: Doutre
authors.forename: F-X
authors.initials: FX
authors.lastname: Lesage
authors.forename: M-A
authors.initials: MA
authors.lastname: Richard
authors.forename: C
authors.initials: C
authors.lastname: Picard-Dahan
authors.forename: M
authors.initials: M
authors.lastname: Beylot-Barry
authors.forename: P
authors.initials: P
authors.lastname: Bernard
authors.forename: B
authors.initials: B
authors.lastname: Crickx
authors.forename: V
authors.initials: V
authors.lastname: Descamps
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010392:Pemphigus / Q000188:drug therapy* / Q000276:immunology*; D012008:Recurrence; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D000305:Adrenal Cortex Hormones; D016756:Immunoglobulins, Intravenous